Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Cuende, B. Pérez, M. Ardanaz, J. Guinea, J.C. Vesga.
Macrophage activation syndrome associated to systemic onset juvenile idiopathic arthritis.
Clin Exp Rheumatol, 19 (2001), pp. 764-765
[2.]
R. Schneider, R.M. Laxer.
Systemic onset juvenile rheumatoid arthritis.
Baillière's Clin Rheumatol, 12 (1998), pp. 245-271
[3.]
S. Yokota, T. Miyamae, T. Imagawa, N. Iwata, S. Katakura, M. Mori, et al.
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
Arthtritis Rheum, 52 (2005), pp. 818-825
[4.]
F. De Benedetti, A. Raveli, A. Martini.
Cytokines in juvenile rheumatoid arthritis.
Curr Opin Rheumatol, 9 (1997), pp. 428-433
[5.]
V. Pascual, F. Allantaz, E. Arce, M. Punaro, J. Banchereau.
Role of interleukin-1(IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.
J Exp Med, 201 (2005), pp. 1479-1486
[6.]
B. Bresnihan, J.M. Álvaro-Gracia, M. Cobby, M. Doherty, Z. Domljan, P. Emery, et al.
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
Arthtritis Rheum, 41 (1998), pp. 2196-2204
[7.]
S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, L.W. Moreland, et al.
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist in combination wit methotrexate.
Arthtritis Rheum, 46 (2002), pp. 614-624
[8.]
M.H. Schiff, G. DiVittorio, J. Tesser, R. Fleischmann, J. Schechtman, S. Hartman, et al.
The safety of anakinra in high-risk patients with active rheumatoid arthritis.
Arthtritis Rheum, 50 (2004), pp. 1752-1760
[9.]
J. Tesser, R. Fleischmann, R. Dore, R. Bennett, A. Solinger, T. Joh, et al.
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
J Rheumatol, 31 (2004), pp. 649-654
[10.]
P.I. Irigoyen, J. Olson, C. Hom, N.T. Ilowite.
Treatment of systemic onset juvenile rheumatoid arthritis with anakinra.
Arthritis Rheum, 50 (2004), pp. S437
[11.]
M. Henrickson.
Efficacy of anakinra in refractory systemic arthritis.
Arthritis Rheum, 50 (2004), pp. S438
[12.]
A.A. Fitzgerald, S.A. LeClercq, A. Yan, J.E. Homik, C.A. Dinarello.
Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Arthritis Rheum, 52 (2005), pp. 1794-1803
[13.]
N.J. Dailey, I. Aksentijevich, J.J. Chae, R. Wesley, C. Snyder, M. Magalnick, et al.
Interleukin 1 receptor antagonist anakinra in the treatment of neonatal onset multisystem inflammatory disease.
Arthritis Rheum, 50 (2004), pp. S440
Copyright © 2006. Elsevier España S.L Barcelona
